Fluoroquinolone safety profiles - A review

Today's Therapeutic Trends

Volumn 20, Issue 4, 2002, Pages 419-433

  Tillotson, Glenn S ^a   Ball, Peter ^a  

^a Fusion MD Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; FLEROXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; LIVER TOXICITY; NEUROTOXICITY; PHOTOTOXICITY; REVIEW; SKIN TOXICITY; TENDON INJURY; VERTIGO;

EID: 0036892379     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Mandell L and Tillotson G: Safety of fluoroquinolones: An update. Can. J. Inf. Dis. 13:54-61, 2002.
2. Rothschild E and Saint-Pierre A: Tavanic-Informations Importantes de Pharmacovigilance Concernant Tavanic (Levofloxacin). Division of Pharmacovigilance, Dept. of Health, Paris, France, Dec. 17, 2001.
3. Smith-Kline Beecham Receives Non-Approval Letter from FDA on Gemifloxacin. http://www.sb.com., December 7, 2000.
4. Domagala JM: Structure-activity and structure side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. Antimicrob. Chemother. 33:685-706, 1994.
5. Lasser KE, Allen PD, Woolhandler SJ, et al.: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287(17):2215-2220, 2002.
6. Ball P, Mandell L, Niki Y and Tillotson G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 21:407-421, 1999.
7. Breen J, Skuba K and Grasela D: Safety and tolerability of gatifloxacin, an advanced generation 8-methoxy fluoroquinolone. J. Respir. Dis. 20(Suppl.):70-76, 1999.
8. Tillotson FS and Rybak MJ: New milestones achieved in fluoroquinolone safety. Pharmacotherapy 21:358-360, 2001.
9. Wilton LV, Pearce GL and Mann RD: A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br. J. Clin. Pharmacol. 41:277-284, 1996.
10. Loffeld RJLF and Flendrig JA: Pseudomembranous colitis under administration of norfloxacin. Ned. Tijdschr. Geneeskd. 134(2):83, 1990.
11. Golledge CL, Carson CF, O'Neill GL, et al.: Ciprofloxacin and Clostridium difficile-associated diarrhoea. J. Antimicrob Chemother. 30:141-147, 1992.
12. Langan C, Cranfield R, Breisch SA, et al.: Randomized double-blind study of grepafloxacin verses amoxicillin in patients with acute exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 40(Suppl. A):63-72, 1997.
13. Stahlmann R and Schwabe R: Safety profile of grepafloxacin compared with other fluoroquinolones. J. Antimicrob. Chemother. 40(Suppl. A):83-92, 1997.
14. Halliwell RF, Davey PG and Lambert JJ: Antagonism of GABA-A receptors by 4-quinolones. J. Antimicrob. Chemother. 31:457-462, 1993.
15. Lode H: Potential interactions of the extended spectrum fluoroquinolones with the CNS. Drug Saf 21:123-135, 1999.
16. Cohen JS: Peripheral neuropathy associated with fluoroquinolones. Ann. Pharmacother. 35(12):1540-1547, 2001.
17. Tillotson GS: Comment: Peripheral neuropathy syndrome and fluoroquinolones. Ann. Pharmacother. 35(12):1673-1674, 2001.
18. Ferguson J: Fluoroquinolone photosensitization: A review of clinical and laboratory studies. Photochem. Photobiol. 62:954-958, 1995.
19. Bertino J Jr and Fish D: The safety profile of the fluoroquinolones. Clin. Ther. 22:798-817, 2000.
20. Gemifloxacin discontinued in U.S.A. Press release, GlaxoSmithKline, Research Triangle Park, NC, 2001.
21. Wagai N and Tawara K: Possible reasons for differences in phototoxic potential of 5 quinolone antibacterial agents: Generation of toxic oxygen. Free Radic. Res. 17:387-398, 1992.
22. Marutani K, Matsumoto M, Otabe Y, et al.: Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at position 8 in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother. 37:2217-2223, 1993.
23. Fuchs S, Simon Z and Brezis M: Fatal hepatic failure associated with ciprofloxacin. Lancet 343:738-739, 1994.
24. Lucena MI, Andrade RJ, Sanchez-Martinez H, et al.: Norfloxacin-induced cholestatic jaundice. Am. J. Gastroenterol. 93:2309-2311, 1998.
25. Blum A: Ofloxacin induced severe hepatitis (Letter). South. Med. J. 84:1158, 1991.
26. Chen HJL, Block KJ and Maclean JA: Acute eosinophilic hepatitis from trovafloxacin. N. Eng. J. Med. 342:359-360, 2000.
27. Suchard J: Review: Wherefore withdrawal? The science behind recent drug withdrawals and warnings. Int. J. Med. Toxicol. 4:15, 2001.
28. Henann NE and Zambie MF: Gatifloxacin-associated acute hepatitis. Pharmacotherapy 21:1579-1582, 2001.
29. Nicholson SC, Webb CD and Moellering RC Jr: Antimicrobial-associated acute hepatitis. Pharmacotherapy 22:794-797, 2002.
30. Garcia-Rodriquez L, Stricker BM and Zimmerman HJ: Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch. Intern. Med. 156:1327-1332, 1996.
31. Yagawa K: Latest industry information on the safety profile of levofloxacin in Japan. Chemotherapy 47(Suppl. 3):38-43, 2001.